A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors

Trial Profile

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Durvalumab (Primary) ; Olaparib (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MEDIOLA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Oct 2017 Results from a cohort ofpatients with relapsed small cell lung cancer from phase II part of this study (n=38) presented at the 18th World Conference on Lung Cancer
    • 09 Oct 2017 Planned End Date changed from 27 Jul 2018 to 27 Jun 2018.
    • 09 Oct 2017 Planned primary completion date changed from 27 Jul 2018 to 27 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top